Spread of Klebsiella pneumoniae carbapenemase-2-producing Klebsiella pneumoniae clones in Asia

References

• 1 Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case–control study. J. Microbiol. Immunol. Infect. 45(2), 113–119 (2012).
  MedlineGoogle Scholar
• 2 Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents. Chemother. 56(4), 2108–2113 (2012).
  Medline CASGoogle Scholar
• 3 Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumonia carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55(7), 943–950 (2012).
  Medline CASGoogle Scholar
• 4 Jean SS, Lee WS, Hsueh PR. Nationwide spread of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan. J. Microbiol. Immunol. Infect. 46(5), 317–319 (2013).
  Medline CASGoogle Scholar
• 5 Centers for Disease Control and Prevention of Taiwan. The monitor report, from Taiwanese Nosocomial Infection Surveillance System, in the third quarter of 2012 (written in Chinese). www.taichung.gov.tw/public/Data/31411292471.pdf
  Google Scholar
• 6 Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J. Antimicrob. Chemother. 66(2), 307–312 (2011).
  Medline CASGoogle Scholar
• 7 Ma L, Lu PL, Siu LK, Hsieh MH. Molecular typing and resistance mechanisms of imipenem-non-susceptible Klebsiella pneumoniae in Taiwan: results from the Taiwan surveillance of antibiotic resistance (TSAR) study, 2002–2009. J. Med. Microbiol. 62(1), 101–107 (2013).
  Medline CASGoogle Scholar
• 8 Hung KH, Yan JJ, Lu JJ, Chen HM, Wu JJ. Characterization of the modified Hodge test-positive isolates of Enterobacteriaceae in Taiwan. J. Microbiol. Immunol. Infect. 46(1), 35–40 (2013).
  Medline CASGoogle Scholar
• 9 Chung KP, Tseng SP, Huang YT, Tsai TH, Teng LJ, Hsueh PR. Arrival of Klebsiella pneumoniae carbapenemase (KPC)-2 in Taiwan. J. Antimicrob. Chemother. 66(5), 1182–1184 (2011).
  Medline CASGoogle Scholar
• 10 Lee CM, Liao CH, Lee WS et al. Outbreak of Klebsiella pneumonia carbapenemase-2-producing K. pneumonia sequence type 11 in Taiwan in 2011. Antimicrob. Agents. Chemother. 56(10), 5016–5022 (2012).
  Medline CASGoogle Scholar
• 11 Chiu SK, Wu TL, Chuang YC et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS ONE 8(7), e69428–e69434 (2013).
  Medline CASGoogle Scholar
• 12 Balm MN, Ngan G, Jureen R, Lin RT, Teo J. Molecular characterization of newly emerged bla_KPC-2-producing Klebsiella pneumoniae in Singapore. J. Clin. Microbiol. 50(2), 475–476 (2012).
  Medline CASGoogle Scholar
• 13 Koyano S, Saito R, Nagai R et al. Molecular characterization of carbapenemase-producing clinical isolates of Enterobacteriaceae in a teaching hospital, Japan. J. Med. Microbiol. 62(3), 446–450 (2013).
  Medline CASGoogle Scholar
• 14 Yoo JS, Kim HM, Yoo JI et al. Detection of clonal KPC-2-producing Klebsiella pneumonia ST258 in Korea during nationwide surveillance in 2011. J. Med. Microbiol. 62(9), 1338–1342 (2013).
  Medline CASGoogle Scholar
• 15 Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. β-lactamase production in key Gram-negative pathogen isolates from the Arabian Peninsula. Clin. Microbiol. Rev. 26(3), 361–380 (2013).
  Medline CASGoogle Scholar
• 16 Chen YT, Lin JC, Fung CPet al. KPC-2-encoding plasmids from Escherichia coli and Klebsiella pneumoniae in Taiwan. J. Antimicrob. Chemother. doi:10.1093/jac/dkt409 (2013) (Epub ahead of print).
  Google Scholar
• 17 Huang SR, Liu MF, Lin CF, Shi ZY. Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infections. J. Microbiol. Immunol. Infect. doi:10.1016/j.jmii.08.029 (2012) (Epub ahead of print).
  Google Scholar
• 18 Spanu T, De Angelis G, Cipriani M et al. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents. Chemother. 56(8), 4516–4518 (2012).
  Medline CASGoogle Scholar
• 19 Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47(5), 1611–1612 (2009).
  MedlineGoogle Scholar
• 20 Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamics dosing strategy for meropenem. J. Clin. Pharmacol. 43(10), 1116–1123 (2003).
  Medline CASGoogle Scholar
• 21 Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann. Clin. Microbiol. Antimicrob. 11, 32–40 (2012).
  MedlineGoogle Scholar